NextScience "DandiBio KONEX Listing... Trading Starts on the 24th"

[Asia Economy Reporter Hyunseok Yoo] NextScience announced on the 23rd that DandiBioScience (hereinafter DandiBio) will be listed on KONEX.

DandiBio, which is developing new drugs for sepsis and immuno-oncology, will begin trading from the 24th. DandiBio was founded and is currently led by Dr. Youngmin Park, who served as the president of the Korean Society for Immunology and is currently a professor at Konkuk University School of Medicine. He has devoted over 10 years to developing new drugs for sepsis treatment.

DandiBio has pipelines including sepsis therapeutics, antibiotics for super bacteria, and immune enhancers that act as adjuvants for cancer vaccines.

Sepsis requires rapid antibiotic treatment in the early stages of infection to eliminate bacteria. However, endotoxins secreted after antibiotic treatment act on immune cells, inducing secondary immune responses such as cytokine storms, which can lead to organ failure?a limitation that cannot be prevented. According to the company, there are currently no treatments available worldwide.

The sepsis therapeutic candidate discovered by DandiBio has a dual function: it directly eliminates bacteria and binds to endotoxins secreted during bacterial destruction to control organ failure caused by cytokine storms.

Another core pipeline of DandiBio is an immuno-oncology drug that significantly improves the limited immune induction response of existing cancer vaccines or immune enhancers. It changes the immunosuppressive or resistant tumor microenvironment to enable the immune mechanism to attack tumor cells. By integrating a drug delivery platform independently developed through long-term research, it is expected to have a synergistic effect when combined with immune checkpoint inhibitors in terms of efficacy.

NextScience is conducting its bio business through its subsidiary DandiBio and investment company NanoGen. Recently, it decided to invest $5 million (approximately 6 billion KRW) in Immunomic Therapeutics (hereinafter Immunomic), a subsidiary of HLB.

A company representative stated, “DandiBio will build the HBS (HLB Bio eco-System) together with NextScience and HLB, HLB Life Science’s Immunomic Therapeutics in the U.S., which have global clinical experience, and seek growth through organic cooperation among the companies.”

This content was produced with the assistance of AI translation services.